Ocular Therapeutix (OCUL) Competitors

$9.14 -0.14 (-1.54%)

As of 03:03 PM Eastern

OCUL vs. CYTK, NUVL, IBRX, QGEN, and ACLX

Should you buy Ocular Therapeutix stock or one of its competitors? MarketBeat compares Ocular Therapeutix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocular Therapeutix include Cytokinetics (CYTK), Nuvalent (NUVL), ImmunityBio (IBRX), Qiagen (QGEN), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.

How does Ocular Therapeutix compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Cytokinetics had 17 more articles in the media than Ocular Therapeutix. MarketBeat recorded 40 mentions for Cytokinetics and 23 mentions for Ocular Therapeutix. Cytokinetics' average media sentiment score of 0.62 beat Ocular Therapeutix's score of -0.03 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	15 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix has a net margin of -558.24% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Cytokinetics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Ocular Therapeutix has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	105.34	-$784.96M	-$6.84	N/A
Ocular Therapeutix	$51.95M	38.54	-$265.94M	-$1.46	N/A

59.2% of Ocular Therapeutix shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cytokinetics currently has a consensus price target of $98.55, indicating a potential upside of 32.23%. Ocular Therapeutix has a consensus price target of $23.78, indicating a potential upside of 160.01%. Given Ocular Therapeutix's higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Cytokinetics beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Nuvalent?

Ocular Therapeutix (NASDAQ:OCUL) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 10.2% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ocular Therapeutix had 7 more articles in the media than Nuvalent. MarketBeat recorded 23 mentions for Ocular Therapeutix and 16 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.61 beat Ocular Therapeutix's score of -0.03 indicating that Nuvalent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvalent	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	38.54	-$265.94M	-$1.46	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Ocular Therapeutix presently has a consensus price target of $23.78, indicating a potential upside of 160.01%. Nuvalent has a consensus price target of $137.25, indicating a potential upside of 33.51%. Given Ocular Therapeutix's higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Nuvalent	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.88

Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

Nuvalent has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Nuvalent's return on equity of -41.73% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Nuvalent	N/A	-41.73%	-36.87%

Summary

Nuvalent beats Ocular Therapeutix on 9 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Ocular Therapeutix has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$140.98M	59.99	-$351.40M	-$0.85	N/A
Ocular Therapeutix	$51.95M	38.54	-$265.94M	-$1.46	N/A

In the previous week, ImmunityBio had 34 more articles in the media than Ocular Therapeutix. MarketBeat recorded 57 mentions for ImmunityBio and 23 mentions for Ocular Therapeutix. ImmunityBio's average media sentiment score of 0.02 beat Ocular Therapeutix's score of -0.03 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	5 Positive mention(s)	34 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral
Ocular Therapeutix	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix has a net margin of -558.24% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-64.93%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

ImmunityBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 75.85%. Ocular Therapeutix has a consensus price target of $23.78, indicating a potential upside of 160.01%. Given Ocular Therapeutix's higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 69.5% of ImmunityBio shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ImmunityBio beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Qiagen?

Ocular Therapeutix (NASDAQ:OCUL) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Qiagen has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	38.54	-$265.94M	-$1.46	N/A
Qiagen	$2.09B	3.31	$424.88M	$1.91	17.58

Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

In the previous week, Ocular Therapeutix had 6 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Ocular Therapeutix and 17 mentions for Qiagen. Qiagen's average media sentiment score of 0.13 beat Ocular Therapeutix's score of -0.03 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ocular Therapeutix currently has a consensus price target of $23.78, suggesting a potential upside of 160.01%. Qiagen has a consensus price target of $46.38, suggesting a potential upside of 38.09%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Qiagen	0 Sell rating(s)	7 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Qiagen has a net margin of 19.16% compared to Ocular Therapeutix's net margin of -558.24%. Qiagen's return on equity of 14.09% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Qiagen	19.16%	14.09%	8.26%

Summary

Qiagen beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Arcellx?

Arcellx (NASDAQ:ACLX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Ocular Therapeutix has a net margin of -558.24% compared to Arcellx's net margin of -1,027.26%. Arcellx's return on equity of -55.42% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Arcellx has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

In the previous week, Ocular Therapeutix had 22 more articles in the media than Arcellx. MarketBeat recorded 23 mentions for Ocular Therapeutix and 1 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Ocular Therapeutix's score of -0.03 indicating that Arcellx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcellx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.0% of Arcellx shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 8.4% of Arcellx shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Arcellx has higher earnings, but lower revenue than Ocular Therapeutix. Arcellx is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
Ocular Therapeutix	$51.95M	38.54	-$265.94M	-$1.46	N/A

Arcellx currently has a consensus price target of $111.87, suggesting a potential downside of 2.78%. Ocular Therapeutix has a consensus price target of $23.78, suggesting a potential upside of 160.01%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Ocular Therapeutix beats Arcellx on 9 of the 17 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.00B	$3.03B	$6.27B	$12.13B
Dividend Yield	N/A	1.93%	2.78%	5.23%
P/E Ratio	-6.26	17.66	20.53	25.45
Price / Sales	38.54	269.64	545.62	75.37
Price / Cash	N/A	55.41	27.81	36.29
Price / Book	2.98	4.11	9.60	6.64
Net Income	-$265.94M	$72.19M	$3.55B	$333.40M
7 Day Performance	-5.82%	-1.34%	-0.34%	-0.45%
1 Month Performance	4.04%	3.03%	6.09%	7.83%
1 Year Performance	23.75%	44.38%	38.53%	35.63%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	3.2092 of 5 stars	$9.15 -1.5%	$23.78 +160.0%	+30.5%	$2.00B	$51.95M	N/A	230
CYTK Cytokinetics	2.9144 of 5 stars	$66.05 +4.3%	$90.55 +37.1%	+135.3%	$7.87B	$88.04M	N/A	250	Earnings Report Analyst Upgrade Options Volume
NUVL Nuvalent	3.0789 of 5 stars	$102.62 +3.6%	$137.25 +33.7%	+49.7%	$7.79B	N/A	N/A	40	Earnings Report Analyst Revision
IBRX ImmunityBio	2.8424 of 5 stars	$7.43 +4.5%	$14.40 +93.8%	+291.8%	$7.31B	$113.29M	N/A	590	Trending News Earnings Report Analyst Revision
QGEN Qiagen	4.5647 of 5 stars	$33.90 -1.0%	$47.09 +38.9%	-26.0%	$7.06B	$2.09B	16.81	5,654	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. CYTK, NUVL, IBRX, QGEN, and ACLX

How does Ocular Therapeutix compare to Cytokinetics?

Summary

How does Ocular Therapeutix compare to Nuvalent?

Summary

How does Ocular Therapeutix compare to ImmunityBio?

Summary

How does Ocular Therapeutix compare to Qiagen?

Summary

How does Ocular Therapeutix compare to Arcellx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. CYTK, NUVL, IBRX, QGEN, and ACLX

How does Ocular Therapeutix compare to Cytokinetics?

Does the media favor CYTK or OCUL?

Is CYTK or OCUL more profitable?

Which has more risk & volatility, CYTK or OCUL?

Which has higher valuation & earnings, CYTK or OCUL?

Do insiders & institutionals believe in CYTK or OCUL?

Do analysts recommend CYTK or OCUL?

Summary

How does Ocular Therapeutix compare to Nuvalent?

Do institutionals and insiders believe in OCUL or NUVL?

Does the media refer more to OCUL or NUVL?

Which has better valuation & earnings, OCUL or NUVL?

Do analysts rate OCUL or NUVL?

Which has more volatility and risk, OCUL or NUVL?

Is OCUL or NUVL more profitable?

Summary

How does Ocular Therapeutix compare to ImmunityBio?

Which has preferable valuation and earnings, IBRX or OCUL?

Does the media refer more to IBRX or OCUL?

Is IBRX or OCUL more profitable?

Which has more risk and volatility, IBRX or OCUL?

Do analysts rate IBRX or OCUL?

Do institutionals and insiders believe in IBRX or OCUL?

Summary

How does Ocular Therapeutix compare to Qiagen?

Which has better earnings and valuation, OCUL or QGEN?

Which has more volatility & risk, OCUL or QGEN?

Does the media favor OCUL or QGEN?

Do institutionals & insiders have more ownership in OCUL or QGEN?

Do analysts rate OCUL or QGEN?

Is OCUL or QGEN more profitable?

Summary

How does Ocular Therapeutix compare to Arcellx?

Is ACLX or OCUL more profitable?

Which has more risk & volatility, ACLX or OCUL?

Does the media refer more to ACLX or OCUL?

Do insiders and institutionals believe in ACLX or OCUL?

Which has stronger earnings & valuation, ACLX or OCUL?

Do analysts recommend ACLX or OCUL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools